Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trospium chloride/xanomeline - Karuna Therapeutics

Next Previous
Drug Profile

Trospium chloride/xanomeline - Karuna Therapeutics

Alternative Names: Karuna-Xanomeline-Trospium; KarXT; Trospium chloride/LY 246708; Trospium chloride/xanomeline tartrate; Xanomeline/trospium chloride - Karuna Therapeutics

Latest Information Update: 12 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Karuna Pharmaceuticals
  • Developer Karuna Therapeutics; ZAI Lab
  • Class Analgesics; Antidementias; Antipsychotics; Antispasmodics; Benzhydryl compounds; Benzilates; Esters; Nortropanes; Pyridines; Small molecules; Spiro compounds; Thiadiazoles; Urologics
  • Mechanism of Action Muscarinic M1 receptor agonists; Muscarinic M4 receptor agonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Schizophrenia
  • Phase III Alzheimer's disease
  • No development reported Dementia
  • Discontinued Pain

Most Recent Events

  • 06 Apr 2024 Interim efficacy and adverse events data from the phase III EMERGENT-4 trial in schizophrenia released by Bristol-Myers Squibb
  • 06 Apr 2024 Interim pooled efficacy and adverse events data from phase III EMERGENT-4 and EMERGENT-5 trials in Schizophrenia released by Karuna Therapeutics
  • 18 Mar 2024 Karuna Therapeutics has been acquired by Bristol-Myers Squibb
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top